AbbVie Inc. (NYSE:ABBV) Given Consensus Rating of “Moderate Buy” by Analysts

AbbVie Inc. (NYSE:ABBV) has been given an average rating of “Moderate Buy” by the twenty-three analysts that are presently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $248.1053.

Several research firms have recently issued reports on ABBV. Bank of America upped their price objective on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. UBS Group reissued a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. Finally, Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th.

AbbVie Trading Up 1.0%

Shares of ABBV opened at $216.13 on Thursday. The firm has a market cap of $381.98 billion, a PE ratio of 163.73, a P/E/G ratio of 0.87 and a beta of 0.36. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a fifty day moving average price of $226.15 and a 200-day moving average price of $216.99.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 524.24%.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the business. Chelsea Counsel Co. purchased a new position in shares of AbbVie during the third quarter worth $26,000. Westend Capital Management LLC acquired a new stake in AbbVie during the 4th quarter worth about $29,000. Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie during the 3rd quarter valued at about $31,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter valued at about $26,000. Finally, Caitlin John LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at about $33,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.